<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="B01AC56" />
<ATC code="C10BX01" />
<ATC code="C10BX02" />
<ATC code="C10BX04" />
<ATC code="M01BA03" />
<ATC code="N02BA01" />
<ATC code="N02BA51" />
<ATC code="N02BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation action</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If the administration of the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Increase of the dosage of the ciclosporin according to testing of the blood concentrations. Reduction of the dosage if the ticlopidine is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and testing of the plasma concentrations of phenytoin.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>521-TICLOPIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline). </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly monitoring of the theophyllinemia; if there is reason for it, adjustment of the dosage of the theophylline during the treatment with the ticlopidine and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
